KRM22’s finals to December 2025 report performance in line with the January TU, including ARR growth of 19% and cash (no debt) of £5.2m. After the successful November £9.2m placing, enabling both a robust debt-free balance sheet and the capacity to invest, the group continues to execute in staff and capabilities, product set expansion, and development in additional capital markets where KRM22 products have opportunities as customers’ regulatory demands intensify. FY25 reported ARR growth of £1.6 ....
